Pharma BD Deal Intelligence
Novartis and GSK complete oncology and vaccines swap, with Novartis acquiring GSKs oncology products including kidney cancer therapy Votrient and breast cancer…
GSK acquired Novartis' oncology division for $16B.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired GSK's oncology portfolio for $16B as part of the 2014 three-part asset swap between GSK and Novartis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / GlaxoSmithKline plc (this deal) | 2014 | $16.0B | 81 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2014 deals · Novartis AG deals · Oncology deals